Hofseth BioCare ASA
Oslo Stock ExchangeTotal Valuation
Hofseth BioCare ASA carries a market capitalization of 604.47M, placing it among publicly traded companies globally. Its enterprise value stands at 891.32M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 604.47M |
| Enterprise Value | 891.32M |
Share Statistics
Hofseth BioCare ASA currently has 395.08M shares outstanding.
| Shares Outstanding | 395.08M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 2.40, and the price-to-book ratio stands at 142.99.
| PE Ratio | N/A |
| PS Ratio | 2.40 |
| PB Ratio | 142.99 |
| P/TBV Ratio | -4.01 |
| P/FCF Ratio | 29.73 |
| P/OCF Ratio | -38.70 |
Enterprise Valuation
| EV / Sales | 3.64 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 19.32 |
Financial Position
Hofseth BioCare ASA maintains a current ratio of 0.52, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -316.91, indicating conservative leverage, while an interest coverage ratio of -4.49 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.52 |
| Quick Ratio | 0.19 |
| Debt / Equity | -316.91 |
| Debt / EBITDA | -3.03 |
| Interest Coverage | -4.49 |
Financial Efficiency
| Return on Equity (ROE) | -3,364.92 |
| Return on Assets (ROA) | -36.80 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.66 |
Taxes
| Income Tax | 176,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Hofseth BioCare ASA's stock has declined approximately -14.04494% over the past 52 weeks. The 50-day moving average sits at 1.28, while the 200-day moving average is 1.47.
| Beta (5Y) | N/A |
| 52-Week Price Change | -14.04494% |
| 50-Day Moving Average | 1.28 |
| 200-Day Moving Average | 1.47 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Hofseth BioCare ASA generated 244.95M in revenue and converted that into -138.33M in net income, yielding earnings per share of -0.33. EBITDA reached -116.46M, while operating income came in at -116.46M.
| Revenue | 244.95M |
| Gross Profit | 92.15M |
| Operating Income | -116.46M |
| Pretax Income | -138.16M |
| Net Income | -138.33M |
| EBITDA | -116.46M |
| EBIT | -116.46M |
| Earnings Per Share (EPS) | -0.33 |
Balance Sheet
Hofseth BioCare ASA holds 49.11M in cash and equivalents against 353.28M in total debt, resulting in a net debt position of -49.11M. Total book value stands at 4.11M, with working capital of -125.02M providing operational flexibility.
| Cash & Cash Equivalents | 49.11M |
| Total Debt | 353.28M |
| Net Debt | -49.11M |
| Equity (Book Value) | 4.11M |
| Book Value Per Share | 0.01 |
| Working Capital | -125.02M |
Cash Flow
Hofseth BioCare ASA produced -15.19M in operating cash flow over the past twelve months. After subtracting -35.35M in capital expenditures, free cash flow totaled -50.54M - equivalent to -0.12 per share.
| Operating Cash Flow | -15.19M |
| Capital Expenditures | -35.35M |
| Free Cash Flow | -50.54M |
| FCF Per Share | -0.12 |
Margins
Hofseth BioCare ASA operates with a gross margin of 37.62, reflecting its pricing power and cost economics. The operating margin of -47.55 and net profit margin of -56.47 provide insight into operational efficiency.
| Gross Margin | 37.62 |
| Operating Margin | -47.55 |
| Pretax Margin | -56.40 |
| Profit Margin | -56.47 |
| EBITDA Margin | -47.55 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -3.67 |
| FCF Yield | 3.36 |
Scores
Hofseth BioCare ASA posts an Altman Z-Score of -0.13, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -0.13 |